Ahmad Mani-Varnosfaderani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmad Mani-Varnosfaderani has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Mehdi Jalali-Heravi
Department of Chemistry, Sharif University of Technology, P.O. Box 11155-9516, Tehran, Iran
7 shared publications - Kambiz Gilany
Department of Integrative Oncology, Breast Cancer Research Center, Motamed Cancer Institute, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran; Reproductive Immunology Research Center, Avicenna Research Institute, The Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
6 shared publications - Abolfazl Valadkhani
Department of Analytical Chemistry, Chemistry and Chemical Engineering Research Center of Iran, P. O. Box 14335-186, Tehran, Iran
4 shared publications M. Asadollahi-Baboli
4 shared publications- Mohammad Asadollahi-Baboli
Department of Chemistry, Faculty of Science, Babol Noshirvani University of Technology, Babol, Iran
4 shared publications - Yadollah Yamini
Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, P.O. Box 14115-175, Tehran, Iran
4 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (5) , 146
From known chemical space to unannotated metabolites: a cluster-guided retention-time driven framework for biologically informed annotation
- 26 August 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (5) , 146
Open AccessFrom known chemical space to unannotated metabolites: a cluster-guided retention-time driven framework for biologically informed annotation
- 20 January 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 3253-3272
General structure-activity relationship models for the inhibitors of Adenosine receptors: A machine learning approach
Adenosine receptors (A1, A2a, A2b, A3) play critical roles in cellular signaling and are implicated in various physiological and pathological processes, including inflammations and cancer. The main aim of this research was to investigate structure–activity relationships (SAR) to derive models that describe the selectivity and activity of inhibitors targeting Adenosine receptors. Structural information for 16,312 inhibitors was collected from BindingDB and analyzed using machine learning methods. 450 molecular descriptors were calculated for each molecule and compounds were classified based on their activity levels and therapeutic targets. The variable importance in projection (VIP) algorithm identified key discriminating features. Classification models were built using supervised Kohonen networks (SKN) and counter-propagation artificial neural networks (CPANN) algorithms. Model validity was assessed via cross-validation, applicability domain analysis, and test sets. These models were then used to screen a random subset of 2 million molecules from the ZINC database. Three descriptors—hydrophilic factor (Hy), ratio of multiple path count over path count (PCR), and asphericity (ASP)—were identified as critical for discriminating active and inactive inhibitors. SKN models exhibited high sensitivity (0.88–0.99) and yielded an average area under the curve (AUC) of 0.922 for virtual screening. This study aimed to enhance the development of highly selective Adenosine receptor ligands for diverse therapeutic applications by identifying critical molecular features specific to each isoform.
- 20 January 2025
- Published by Springer Nature in Molecular Diversity
- Vol. 29 (4) , 3253-3272
General structure-activity relationship models for the inhibitors of Adenosine receptors: A machine learning approach
Adenosine receptors (A1, A2a, A2b, A3) play critical roles in cellular signaling and are implicated in various physiological and pathological processes, including inflammations and cancer. The main aim of this research was to investigate structure–activity relationships (SAR) to derive models that describe the selectivity and activity of inhibitors targeting Adenosine receptors. Structural information for 16,312 inhibitors was collected from BindingDB and analyzed using machine learning methods. 450 molecular descriptors were calculated for each molecule and compounds were classified based on their activity levels and therapeutic targets. The variable importance in projection (VIP) algorithm identified key discriminating features. Classification models were built using supervised Kohonen networks (SKN) and counter-propagation artificial neural networks (CPANN) algorithms. Model validity was assessed via cross-validation, applicability domain analysis, and test sets. These models were then used to screen a random subset of 2 million molecules from the ZINC database. Three descriptors—hydrophilic factor (Hy), ratio of multiple path count over path count (PCR), and asphericity (ASP)—were identified as critical for discriminating active and inactive inhibitors. SKN models exhibited high sensitivity (0.88–0.99) and yielded an average area under the curve (AUC) of 0.922 for virtual screening. This study aimed to enhance the development of highly selective Adenosine receptor ligands for diverse therapeutic applications by identifying critical molecular features specific to each isoform.
- Open Access
- 3 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Deriving general structure–activity/selectivity relationship patterns for different subfamilies of cyclin-dependent kinase inhibitors using machine learning methods
Cyclin-dependent kinases (CDKs) play essential roles in regulating the cell cycle and are among the most critical targets for cancer therapy and drug discovery. The primary objective of this research is to derive general structure–activity relationship (SAR) patterns for modeling the selectivity and activity levels of CDK inhibitors using machine learning methods. To accomplish this, 8592 small molecules with different binding affinities to CDK1, CDK2, CDK4, CDK5, and CDK9 were collected from Binding DB, and a diverse set of descriptors was calculated for each molecule. The supervised Kohonen networks (SKN) and counter propagation artificial neural networks (CPANN) models were trained to predict the activity levels and therapeutic targets of the molecules. The validity of models was confirmed through tenfold cross-validation and external test sets. Using selected sets of molecular descriptors (e.g. hydrophilicity and total polar surface area) we derived activity and selectivity maps to elucidate local regions in chemical space for active and selective CDK inhibitors. The SKN models exhibited prediction accuracies ranging from 0.75 to 0.94 for the external test sets. The developed multivariate classifiers were used for ligand-based virtual screening of 2 million random molecules of the PubChem database, yielding areas under the receiver operating characteristic curves ranging from 0.72 to 1.00 for the SKN model. Considering the persistent challenge of achieving CDK selectivity, this research significantly contributes to addressing the issue and underscores the paramount importance of developing drugs with minimized side effects.
- 3 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessDeriving general structure–activity/selectivity relationship patterns for different subfamilies of cyclin-dependent kinase inhibitors using machine learning methods
Cyclin-dependent kinases (CDKs) play essential roles in regulating the cell cycle and are among the most critical targets for cancer therapy and drug discovery. The primary objective of this research is to derive general structure–activity relationship (SAR) patterns for modeling the selectivity and activity levels of CDK inhibitors using machine learning methods. To accomplish this, 8592 small molecules with different binding affinities to CDK1, CDK2, CDK4, CDK5, and CDK9 were collected from Binding DB, and a diverse set of descriptors was calculated for each molecule. The supervised Kohonen networks (SKN) and counter propagation artificial neural networks (CPANN) models were trained to predict the activity levels and therapeutic targets of the molecules. The validity of models was confirmed through tenfold cross-validation and external test sets. Using selected sets of molecular descriptors (e.g. hydrophilicity and total polar surface area) we derived activity and selectivity maps to elucidate local regions in chemical space for active and selective CDK inhibitors. The SKN models exhibited prediction accuracies ranging from 0.75 to 0.94 for the external test sets. The developed multivariate classifiers were used for ligand-based virtual screening of 2 million random molecules of the PubChem database, yielding areas under the receiver operating characteristic curves ranging from 0.72 to 1.00 for the SKN model. Considering the persistent challenge of achieving CDK selectivity, this research significantly contributes to addressing the issue and underscores the paramount importance of developing drugs with minimized side effects.
- Open Access
- 9 February 2024
- Published by Elsevier in Food Chemistry: X
- Vol. 21, 101213
Combining ion mobility spectrometry and chemometrics for detecting synthetic colorants in black tea: A reliable and fast method
- 9 February 2024
- Published by Elsevier in Food Chemistry: X
- Vol. 21, 101213
Open AccessCombining ion mobility spectrometry and chemometrics for detecting synthetic colorants in black tea: A reliable and fast method
- 14 July 2023
- Published by Springer Nature in Metabolomics
- Vol. 19 (7) , 1-10
Potential metabolic biomarkers of critical limb ischemia in people with type 2 diabetes mellitus
Introduction Type 2 diabetes mellitus (T2DM) is a significant risk factor for the development of critical limb ischemia (CLI), the most advanced stage of peripheral arterial disease. The concurrent existence of T2DM and CLI often leads to adverse outcomes, namely limb amputation. Objective To identify biomarkers for improving the screening of CLI in high-risk people with T2DM. Methods We investigated metabolome profiles in serum samples of 113 T2DM people with CLI (n = 23, G2) and without CLI (n = 45, G0: no lower limb stenosis (LLS) and n = 45, G1: LLS < 50%), using hydrogen nuclear magnetic resonance (1H NMR) approach. Principle component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were used to analyze 1H NMR data. Results Twenty potential metabolites that could discriminate people with T2DM and CLI (G2) from non-CLI patients without LLS (G0) were determined in serum samples. The correct percent of classification for the PLS-DA model for the test set samples was 85% (n = 20) and 100% (n = 5) for G0 and G2 groups, respectively. Non-CLI patients with LLS < 50% (G1) were projected on the PCA abstract space built using 20 discriminatory metabolites. Eleven people with T2DM and LLS < 50% were prospectively followed, and their ankle-brachial index (ABI) was measured after 4 years. A promising agreement existed between the PCA model's predictions and those obtained by ABI values. Conclusion The findings suggest that confirmation of blood potential metabolic biomarkers as a complement to ABI for screening of CLI in a large group of high-risk people with T2DM is needed.
- 14 July 2023
- Published by Springer Nature in Metabolomics
- Vol. 19 (7) , 1-10
Potential metabolic biomarkers of critical limb ischemia in people with type 2 diabetes mellitus
Introduction Type 2 diabetes mellitus (T2DM) is a significant risk factor for the development of critical limb ischemia (CLI), the most advanced stage of peripheral arterial disease. The concurrent existence of T2DM and CLI often leads to adverse outcomes, namely limb amputation. Objective To identify biomarkers for improving the screening of CLI in high-risk people with T2DM. Methods We investigated metabolome profiles in serum samples of 113 T2DM people with CLI (n = 23, G2) and without CLI (n = 45, G0: no lower limb stenosis (LLS) and n = 45, G1: LLS < 50%), using hydrogen nuclear magnetic resonance (1H NMR) approach. Principle component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) were used to analyze 1H NMR data. Results Twenty potential metabolites that could discriminate people with T2DM and CLI (G2) from non-CLI patients without LLS (G0) were determined in serum samples. The correct percent of classification for the PLS-DA model for the test set samples was 85% (n = 20) and 100% (n = 5) for G0 and G2 groups, respectively. Non-CLI patients with LLS < 50% (G1) were projected on the PCA abstract space built using 20 discriminatory metabolites. Eleven people with T2DM and LLS < 50% were prospectively followed, and their ankle-brachial index (ABI) was measured after 4 years. A promising agreement existed between the PCA model's predictions and those obtained by ABI values. Conclusion The findings suggest that confirmation of blood potential metabolic biomarkers as a complement to ABI for screening of CLI in a large group of high-risk people with T2DM is needed.
- 3 October 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21, S296
530 Airway volatile organic compounds can achieve culture-independent identification of Nontuberculous mycobacteria in people with cystic fibrosis
- 3 October 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21, S296
530 Airway volatile organic compounds can achieve culture-independent identification of Nontuberculous mycobacteria in people with cystic fibrosis
- Open Access
- 13 May 2022
- Published by IOP Publishing in Journal of Breath Research
- Vol. 16 (3) , 031001
Breath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: a pilot study
Pulmonary infections caused by mycobacteria cause significant mortality and morbidity in the human population. Diagnosing mycobacterial infections is challenging. An infection can lead to active disease or remain indolent with little clinical consequence. In patients with pulmonary nontuberculosis mycobacteria (PNTM) identification of infection and diagnosis of disease can take months to years. Our previous studies showed the potential diagnostic power of volatile molecules in the exhaled breath samples to detect active pulmonary M. tuberculosis infection. Herein, we demonstrate the ability to detect the disease status of PNTM in the breath of persons with cystic fibrosis (PwCF). We putatively identified 17 volatile molecules that could discriminate between active-NTM disease (n = 6), indolent patients (n = 3), and those patients who have never cultured an NTM (n = 2). The results suggest that further confirmation of the breath biomarkers as a non-invasive and culture-independent tool for diagnosis of NTM disease in a larger cohort of PwCF is warranted
- 13 May 2022
- Published by IOP Publishing in Journal of Breath Research
- Vol. 16 (3) , 031001
Open AccessBreath biomarkers associated with nontuberculosis mycobacteria disease status in persons with cystic fibrosis: a pilot study
Pulmonary infections caused by mycobacteria cause significant mortality and morbidity in the human population. Diagnosing mycobacterial infections is challenging. An infection can lead to active disease or remain indolent with little clinical consequence. In patients with pulmonary nontuberculosis mycobacteria (PNTM) identification of infection and diagnosis of disease can take months to years. Our previous studies showed the potential diagnostic power of volatile molecules in the exhaled breath samples to detect active pulmonary M. tuberculosis infection. Herein, we demonstrate the ability to detect the disease status of PNTM in the breath of persons with cystic fibrosis (PwCF). We putatively identified 17 volatile molecules that could discriminate between active-NTM disease (n = 6), indolent patients (n = 3), and those patients who have never cultured an NTM (n = 2). The results suggest that further confirmation of the breath biomarkers as a non-invasive and culture-independent tool for diagnosis of NTM disease in a larger cohort of PwCF is warranted